Slide 1: Fourth Quarter F2021 Earnings Presentation
Fourth Quarter F2021 Earnings Presentation May 20, 2021
Slide 2: Forward Looking Statements & Non-IFRS Measures
Forward Looking Statements & Non-IFRS Measures This presentation and the oral statements made during this meeting contain certain statements that constitute forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Such forward-looking statements in
Slide 3: Quarterly Highlights
Quarterly Highlights ▪ Strong business performance shows ATS adapting well to Covid-19 environment ▪ Record Order Bookings (up 30% y/y) & healthy Order Backlog provide good revenue visibility ▪ Revenues up 5% y/y (8% sequentially) driven by strong showing from Life Science, Consumer Products, and En
Slide 4: Q4 F2021 Financial Results
Q4 F2021 Financial Results (C$ mm, except per share data) Q4 F2021 Q4 F2020 Y/Y Change ($) Y/Y Change (%) Revenues $399.9 $382.1 $17.8 4.7% Revenue Growth: Earnings from operations 42.8 24.9 17.9 71.9% Organic 5.4% Adjusted earnings from 49.5 39.3 10.2 26.0% Acquisitions 0.2% operations1 FX. (0.9)%
Slide 5: F2021 Financial Results
F2021 Financial Results (C$ mm, except per share data) F2021 F2020 Y/Y Change ($) Y/Y Change (%) Revenues $1,430.0 $1,429.7 $0.3 0.0% Revenue Growth: Earnings from operations 119.6 95.6 24.0 25.1% Organic (3.0)% Adjusted earnings from 163.2 157.4 5.8 3.7% Acquisitions 2.0% operations1 FX. 1.0% EBITD
Slide 6: Order Bookings & Backlog
Order Bookings & Backlog Order Bookings1,2 Backlog1,2 Quarterly Bookings LTM Bookings $1,626 $1,160 $1,468 $1,452 $1,519 $1,410 $1,370 $956 $985 $939 $942 $909 $403 $435 $463 $368 $356 $325 Q3-F20 Q4-F20 Q1-F21 Q2-F21 Q3-F21 Q4-F21 Q3-F20 Q4-F20 Q1-F21 Q2-F21 Q3-F21 Q4-F21 ▪ Strong quarterly booking
Slide 7: Cash Flow Generation
Cash Flow Generation Cash Flow from Operations1,2 Free Cash Flow1,2 $185 $154 $39 $20 $26 $10 Q4-F20 Q4-F21 F2020 F2021 -$9 -$36 Q4-F20 Q4-F21 F2020 F2021 ▪ Quarterly CFO benefited from lower WC investment Net Debt to Adj. EBITDA1 and higher profitability 1.6x 1.6x 1.4x ▪ Healthy F2021 FCF generatio
Slide 8: Summary
Summary ▪ Record Order Bookings and healthy Order Backlog ▪ Continued focus on margin expansion and deployment of ABM ▪ Activity levels picking up in Transportation; More traditional, non-Covid-19 opportunities in Life Sciences funnel ▪ CFT acquisition completed in late March, 2021 – platform acquis
Slide 9: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures Notice to reader: Non-IFRS measures and additional IFRS measures Throughout this presentation management uses certain non-IFRS measures to evaluate the performance of the Company. The terms “operating margin”, “EBITDA”, “adjusted net inc
Slide 10: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures (C$ mm) F2017 F2018 F2019 F2020 F2021 (C$) Q4 Q4 F2020 F2021 F2020 F2021 Adjusted EBITDA 111.7 133.3 161.9 195.1 200.7 Basic earnings per share 0.14 0.26 0.57 0.70 Restructuring charges 2.3 11.2 - 26.6 14.3 Restructuring charges 0.06 - 0
Slide 11: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures (C$ mm) Q4 Q4 (C$ mm) F2017 F2018 F2019 F2020 F2021 F2020 F2021 F2020 F2021 Net Debt (42.0) 12.0 (124.2) (307.0) (317.3) Adjusted earnings from operations 39.3 49.5 157.4 163.2 111.7 133.3 161.9 195.1 200.7 Adjusted EBITDA Restructuring